Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identify gene expression alterations induced by F-PRT versus S-PRT in a mouse sarcoma model

ABSTRACT: To delineate gene expression changes induced by F-PRT versus S-PRT, we performed transcriptional profiling (RNA-Seq) in skin and bone tissues from a mouse sarcoma model. Differential expression analysis followed by pathway enrichment analysis revealed numerous upregulated pathways by S-PRT, yet unaltered by F-PRT.

ORGANISM(S): Mus musculus

PROVIDER: GSE173944 | GEO | 2021/08/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identify gene expression alterations induced by F-PRT versus S-PRT in a mouse sarcoma model

Project description:Identify gene expression alterations induced by F-PRT versus S-PRT in a mouse sarcoma model

| PRJNA727584 | ENA

Genome-wide chromatin analysis of Ewing sarcoma (ChIP-seq)

Project description:As the second most common malignant bone tumor in children and adolescents, Ewing sarcoma is initiated and exacerbated by a chimeric oncoprotein, most commonly, EWS-FLI1. In this study, we apply epigenomic analysis to characterize the transcription dysregulation in this cancer, focusing on the investigation of super-enhancer and its associated transcriptional regulatory mechanisms. We demonstrate that super-enhancer-associated transcripts are significantly enriched in EWS-FLI1 target genes, contribute to the aberrant transcriptional network of the disease, and mediate the exceptional sensitivity of Ewing sarcoma to transcriptional inhibition. Through integrative analysis, we identify MEIS1 as a super-enhancer-driven oncogene, which co-operates with EWS-FLI1 in transcriptional regulation, and plays a key pro-survival role in Ewing sarcoma. Moreover, APCDD1, another super-enhancer-associated gene, acting as a downstream target of both MEIS1 and EWS-FLI1, is also characterized as a novel tumor-promoting factor in this malignancy. These data delineate super-enhancer-mediated transcriptional deregulation in Ewing sarcoma, and uncover numerous candidate oncogenes which can be exploited for further understanding of the molecular pathogenesis for this disease.

2018-12-04 | GSE109477 | GEO

Mitochondrial proteome analysis reveals that an augmented cytochrome c oxidase assembly and activity potentiates respiratory capacity in sarcoma

Project description:Sarcoma is a type of cancer that developed from transformed mesenchymal cells like bone, cartilage, fat, muscle, etc. and is broadly categorized into two types, bone and soft tissue sarcoma. Solid tumor cells rely on glycolysis for energy production, contrary to the general belief, it was previously reported that sarcoma cells rely on mitochondrial respiration and the respiratory chain inhibitors drugs such as methylglyoxal, metformin, etc. selectively kill sarcoma cells. Therefore, the study of detailed mitochondrial proteomes is essential to understand the basic metabolic requirement of sarcoma mitochondria. Here, we generate a solid fibrosarcoma mouse tumor model by injecting a chemical carcinogen 3-methyl cholanthrene into the left hind leg. Differential proteomic profiling of ultrapure mitochondria from mice fibrosarcoma tissues (ST, n=4) and its contralateral leg muscle tissues (CLT, n=4) was performed using an LTQ orbitrap XL mass spectrometer. We found ~429 mitochondria-associated protein hits in a total of eight mice tissue samples. Most of the mitochondrial respiratory chain (MRC) subunits were unaltered, whereas two mitochondrial complex IV i.e. cytochrome c oxidase subunits were upregulated.

2024-10-17 | PXD044903 | Pride

RNA-Seq in two Ewing sarcoma cell lines: A673 and SKNMC

2018-12-04 | GSE117485 | GEO

Mouse model of sarcoma (STS) to characterize tumor vulnerabilities and identify novel targets for anti-cancer treatment

Project description:For metabolomics study, tumor-bearing mice were starved for 6 hours before sarcoma and skeletal muscles were harvested.

2020-11-10 | ST001611 | MetabolomicsWorkbench

Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy

Project description:This SuperSeries is composed of the following subset Series: GSE21122: Whole-transcript expression data for soft-tissue sarcoma tumors and control normal fat specimens GSE21123: Affymetrix SNP array data for soft tissue sarcoma samples Refer to individual Series

2010-07-05 | E-GEOD-21124 | biostudies-arrayexpress

RUNX3 Facilitates Growth of Ewing Sarcoma Cells

Project description:Ewing sarcoma is an aggressive pediatric small round cell tumor that predominantly occurs in bone. Approximately 85% of Ewing sarcomas harbor the EWS/FLI fusion protein, which arises from a chromosomal translocation, t(11:22)(q24:q12). EWS/FLI interacts with numerous lineage-essential transcription factors to maintain mesenchymal progenitors in an undifferentiated state. We previously showed that EWS/FLI binds the osteogenic transcription factor RUNX2 and prevents osteoblast differentiation. In this study, we investigated the role of another Runt-domain protein, RUNX3, in Ewing sarcoma. RUNX3 participates in mesenchymal-derived bone formation and is a context dependent tumor suppressor and oncogene. RUNX3 was detected in all Ewing sarcoma cells examined, whereas RUNX2 was detected in only 73% of specimens. Like RUNX2, RUNX3 binds to EWS/FLI via its Runt domain. EWS/FLI prevented RUNX3 from activating the transcription of a RUNX-responsive reporter, p6OSE2. Stable suppression of RUNX3 expression in the Ewing sarcoma cell line A673 delayed colony growth in anchorage independent soft agar assays and reversed expression of EWS/FLI-responsive genes. These results demonstrate an important role for RUNX3 in Ewing sarcoma. RNA-seq to compare transcriptiome of control A673 ewing sarcoma cells stably expression a non-target or RUNX3 shRNA

2014-05-01 | E-GEOD-56900 | biostudies-arrayexpress

Proteomics and phosphoproteomics of pan-sarcoma

Project description:we establish a 272 Chinese STS patients cohort containing 12 sarcoma subtypes, well-differentiated liposarcoma (WDLPS), myxoid liposarcoma (MLPS), dedifferentiated liposarcoma (DDLPS), angiosarcoma (AS), undifferentiated sarcoma (UPS), myxofibrosarcoma (MFS), other fibroblastic/myofibroblastic tumors (otherFS), leiomyosarcoma (LMS), rhabdomyosarcoma (RMS), malignant peripheral nerve sheath tumor (MPNST), synovial sarcoma (SS), and epithelioid sarcoma (ES).

2024-01-03 | PXD047297 |

Transcription profiling of Kaposi sarcoma, normal skin and primary cells

Project description:Identification of the relationships of Kaposi sarcoma (KS), normal skin to various cell cultures. The effects of KS herpes virus, the infectious cause of KS, on infected endothelial cells are also investigated.

2004-08-01 | E-MEXP-66 | biostudies-arrayexpress

pediatric sarcoma: rhabdomyosarcoma & Ewing's sarcoma

Project description:Affymetrx U95Av2 GeneChip hybridizations, RNA extracted from primary human pediatric alveolar (aRMS) and embryonal (eRMS) rhabdomyosarcoma, plus primary pediatric Ewing's sarcoma (EWS) Keywords = pediatric sarcoma Keywords = Ewing's sarcoma Keywords = rhabdomyosarcoma Keywords: other

2004-03-13 | GSE967 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data